Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2011 Dec 1;11(2):267–276. doi: 10.1158/1535-7163.MCT-11-0584

Figure 4. Paracrine FGF8f induces terminal granulocytic differentiation of CD34+ cells.

Figure 4

(A) Proliferation analysis of CD34+ cells treated with RA (left) or cultured with RA-OCM (right). (B) Proliferation analysis of CD34+ cells treated with RARαS77A- and FGF8f-OCM. P<0.001; *P<0.004. (C) Granulocytic morphologic differentiation of CD34+ cells treated with RA or RA-OCM at different time points (left). Quantification of granulocytic differentiation (right) of the left panel. (D) FGF8 antibodies neutralized the effect of RA-OCM containing FGF8f on inducing terminal granulocytic differentiation of CD34+ cells.